AAL

AMAG Stock Spirals on Negative FDA News

The stock is eyeing its biggest percentage drop in almost three years

Digital Content Manager
Oct 30, 2019 at 9:34 AM
facebook X logo linkedin


The shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) have been cast to the bottom of the Nasdaq today, following news that a Food and Drug Administration (FDA) advisory committee voted in favor of taking the firm's Makena drug, which is used to reduce the risk of preterm birth, off the market. An official FDA ruling is expected early next year.

The women's healthcare concern is down 26.3% at $9.82 in early trading, just one day after hitting an eight-month high of $13.53 yesterday. Now AMAG is slicing straight through its 80-day moving average -- a trendline that caught several pullbacks in recent months -- and is set to settle south of here for the first time since early August. What's more, the drugmaker is eyeing its biggest one-day drop in almost three years. 

The news has already attracted analyst attention. Piper Jaffray downgraded the security to "underweight" from "neutral" and slashed its price target to $6 from $9. This bear note joins the already underwhelmed brokerage bunch, which has given out seven "hold" or worse ratings, compared to only two "buys." What's more, the consensus 12-month price target of $11.50 was a nearly 15% discount to last night's close. 

While short interest declined in the last reporting period, the 13.41 million shares sold short still represent 40.16% of the stock's available float, and would take almost an entire month to cover at AMAG's average pace of trading.

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.